Shanghai Wibson Biotechnology: difference between revisions

Diff·revision 22 → 23·10:06, 17 Apr 2025

Difference between revision 22 and revision 23 of Shanghai Wibson Biotechnology. 8 lines changed; the page grew by 386 bytes.

Revision 22 — 01:12, 10 Apr 2025 CrudePeptidePearl (talk) restructure 5,514 bytes +201	Revision 23 — 10:06, 17 Apr 2025 VerifyVesna (talk) state the assay for the reference interval 5,900 bytes +386
33	No certification claim by the organisation has been corroborated by this wiki, and its own statements about capability are self-published.{{r\|selfpub}}	33	No certification claim by the organisation has been corroborated by this wiki, and its own statements about capability are self-published.{{r\|selfpub}}
34		34
+		35	== Product range ==
+		36	\| Class \| Representative listings \| Documentation reported \|
+		37	\|---\|---\|---\|
+		38	\| Incretin analogues \| Semaglutide, tirzepatide \| Certificate, purity only \|
+		39	\| Research peptides \| Repair and secretagogue peptides \| Certificate, purity only \|
+		40	\| SARMs \| Bulk and capsuled \| Certificate, variable \|
+		41	\| Injectable oils and raw materials \| Bulk \| Certificate, limited detail \|
+		42
35	== References ==	43	== References ==
36	{{reflist}}	44	{{reflist}}